表紙
市場調査レポート

標的ドラッグデリバリ関連の提携動向:条件・契約内容

Global Targeted Drug Delivery Partnering 2010-2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 309770
出版日 ページ情報 英文 170 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
標的ドラッグデリバリ関連の提携動向:条件・契約内容 Global Targeted Drug Delivery Partnering 2010-2016
出版日: 2016年04月01日 ページ情報: 英文 170 Pages
概要

当レポートでは、世界の標的ドラッグデリバリ(標的薬物送達)関連の企業提携(パートナーシップ)の締結動向やその内容(提携条件)について分析し、近年の企業提携の動向や特徴(契約方式別・開発段階別・治療領域別など)、平均的な取引条件、代表的な取引事例、大手製薬企業の契約動向、近年の提携取引一覧とその内訳といった情報を盛り込んでお届けいたします。

エグゼクティブ・サマリー

第1章 イントロダクション

第2章 標的ドラッグデリバリ関連の企業提携の締結動向

  • イントロダクション
  • 近年の標的ドラッグデリバリ関連の提携動向
  • 大手製薬企業による、標的ドラッグデリバリ関連の提携活動
  • 標的ドラッグデリバリ関連の提携:契約の種類別
  • 標的ドラッグデリバリ関連の提携:治療領域別
  • 公開されている資本取引の条件
    • 支払総額
    • 前払い金
    • マイルストーン払い
    • ロイヤルティ料率

第3章 標的ドラッグデリバリ関連の代表的な資本取引

  • イントロダクション
  • 標的ドラッグデリバリ関連の代表的な資本取引と取引金額

第4章 大手製薬企業による、標的ドラッグデリバリ関連の提携活動

  • イントロダクション
  • 大手製薬企業による、標的ドラッグデリバリ関連の提携活動
  • 標的ドラッグデリバリ関連の大手提携企業のプロファイル

第5章 標的ドラッグデリバリ関連の取引形成一覧

  • イントロダクション
  • 取引形成の一覧

第6章 標的ドラッグデリバリ関連取引形成:技術タイプ別

第7章 提携リソースセンター

  • オンライン提携
  • 提携動向
  • 関連資料

付録

  • 付録1:企業名順(A〜Z)
  • 付録2:治験段階別
    • 創薬
    • 前臨床
    • 第I相
    • 第II相
    • 第III相
    • 認証中
    • 上市済み
    • 処方(製剤)設計
  • 付録3:取引の種類別
    • 資産購入
    • 大手製薬企業のアウトライセンス
    • 共同開発
    • 共同研究開発(R&D)
    • 共同販売
    • 共同プロモーション
    • 共同研究開発合意(CRADA)
    • クロスライセンス
    • 開発
    • 流通
    • 株式購入
    • 評価
    • 助成金
    • 合弁事業
    • ライセンス
    • 訴訟
    • 製造
    • マーケティング
    • 物質移動
    • オプション
    • プロモーション
    • 研究
    • 調停
    • スピンアウト
    • 二次ライセンス
    • 供給
    • 技術移管
    • 契約終了
    • 保証
  • 付録4:治療領域別
  • 付録5:取引種類の定義

Wildwood Venturesについて

  • Current Partnering
  • Current Agreements
  • Current Partnering の最新レポート

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2102tar

‘Targeted Drug Delivery Partnering 2010-2016’ report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

  • Trends in targeted drug delivery partnering deals
  • Top targeted drug delivery deals by value Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Targeted Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Targeted Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Targeted Drug Delivery partnering deals.

The report presents financial deal term values for Targeted Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Targeted Drug Delivery partnering field; both the leading deal values and most active Targeted Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 160 online deal records of actual Targeted Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Targeted Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Targeted Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Targeted Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Targeted Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Targeted Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Targeted Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Targeted Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Targeted Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Targeted Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Targeted Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Targeted Drug Delivery technologies and products.

Key benefits

‘Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’ provides the reader with the following key benefits:

  • In-depth understanding of Targeted Drug Delivery deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Targeted Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Targeted Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Targeted Drug Delivery dealmakers since 2010
  • Insight into terms included in a Targeted Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’ is intended to provide the reader with an in-depth understanding and access to Targeted Drug Delivery trends and structure of deals entered into by leading companies worldwide.

‘Targeted Drug Delivery Partnering Terms and Agreements’ includes:

  • Trends in Targeted Drug Delivery dealmaking in the biopharma industry since 2010
  • Analysis of Targeted Drug Delivery deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Targeted Drug Delivery deals
  • Access to Targeted Drug Delivery contract documents
  • Leading Targeted Drug Delivery deals by value since 2010
  • Most active Targeted Drug Delivery dealmakers since 2010

In ‘Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts’ report provides comprehensive access to available deals and contract documents for over 160 Targeted Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Targeted Drug Delivery dealmaking

  • 2.1. Introduction
  • 2.2. Targeted Drug Delivery partnering over the years
  • 2.3. Most active Targeted Drug Delivery dealmakers
  • 2.4. Targeted Drug Delivery partnering by deal type
  • 2.5. Targeted Drug Delivery partnering by therapy area
  • 2.6. Deal terms for Targeted Drug Delivery partnering
    • 2.6.1. Targeted Drug Delivery partnering headline values
    • 2.6.2. Targeted Drug Delivery deal upfront payments7
    • 2.6.3. Targeted Drug Delivery deal milestone payments
    • 2.6.4. Targeted Drug Delivery royalty rates

Chapter 3 - Leading Targeted Drug Delivery deals

  • 3.1. Introduction
  • 3.2. Top Targeted Drug Delivery deals by value

Chapter 4 - Most active Targeted Drug Delivery dealmakers

  • 4.1. Introduction
  • 4.2. Most active Targeted Drug Delivery dealmakers
  • 4.3. Most active Targeted Drug Delivery partnering company profiles

Chapter 5 - Targeted Drug Delivery contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Targeted Drug Delivery contracts dealmaking directory

Chapter 6 - Targeted Drug Delivery dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Targeted Drug Delivery deals by company A-Z

Appendix 2 - Targeted Drug Delivery deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Targeted Drug Delivery deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Targeted Drug Delivery deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Targeted Drug Delivery partnering since 2010
  • Figure 2: Active Targeted Drug Delivery dealmaking activity- 2010 to 2016
  • Figure 3: Targeted Drug Delivery partnering by deal type since 2010
  • Figure 4: Targeted Drug Delivery partnering by disease type since 2010
  • Figure 5: Targeted Drug Delivery deals with a headline value
  • Figure 6: Targeted Drug Delivery deals with an upfront value
  • Figure 7: Targeted Drug Delivery deals with a milestone value
  • Figure 8: Targeted Drug Delivery deals with a royalty rate value
  • Figure 9: Top Targeted Drug Delivery deals by value since 2010
  • Figure 10: Most active Targeted Drug Delivery dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top